Cited by 5,261Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

Open access

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group·1998·New England Journal of Medicine

DOI 10.1056/nejm199811053391902

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. METHODS: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. RESULTS: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P<0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199811053391902

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Is Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded?: Findings in 356 222 Primary Screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
Stamler, J. (1986) · JAMA · doi:10.1001/jama.1986.03380200061022 · Cited by 1,318
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 665
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537

Show all 21 references

Research works printed but not linked: 4

Peto R, 1985, Circulation, 72, 451
Keech A, 1992, Postgrad Med J, 68, 870
1994, Lancet, 344, 1383
Keech A, 1998, Atherosclerosis, 136, S31

Sorted by citations

Items 801–900 of 1,037

Task Force #4—adherence issues and behavior changes: achieving a long-term solution
Ockene, I. S., Hayman, L. L., Pasternak, R. C., SCHRON, E. B., & Dunbar‐Jacob, J. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02078-8 · Cited by 103
Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events
Greisenegger, S., Müllner, M., Tentschert, S., Lang, W., & Lalouschek, W. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.01.015 · Cited by 103
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study
Macin, S. M., Perna, E. R., Farías, E. F., Franciosi, V. A., Cialzeta, J., Brizuela, M., Medina, F., Tajer, C. D., Doval, H. C., & Badaracco, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.041 · Cited by 103
The Yin–Yang Dynamics of DNA Methylation Is the Key Regulator for Smooth Muscle Cell Phenotype Switch and Vascular Remodeling
Zhuang, J., Luan, P., Li, H., Wang, K., Zhang, P., Xu, Y., & Peng, W. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307923 · Cited by 103
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]
Heart Protection Study Collaborative Group (2005) · BMC Medicine · doi:10.1186/1741-7015-3-6 · Cited by 103
Management of Type 2 Diabetes Mellitus in the Elderly
Rosenstock, J. (2001) · Drugs & Aging · doi:10.2165/00002512-200118010-00003 · Cited by 103
Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction
Ganz, D. A., Kuntz, K. M., Jacobson, G., & Avorn, J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00003 · Cited by 103
Cerebral Vascular Dysfunction During Hypercholesterolemia
Kitayama, J., Faraci, F. M., Lentz, S. R., & Heistad, D. D. (2007) · Stroke · doi:10.1161/strokeaha.107.481879 · Cited by 102
Influence of Pitavastatin on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus
Yamakawa, T., Takano, T., Tanaka, S., Kadonosono, K., & Terauchi, Y. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e562 · Cited by 102
Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women
Mizuno, K., Nakaya, N., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., Uchiyama, S., & Nakamura, H. (2008) · Circulation · doi:10.1161/circulationaha.106.671826 · Cited by 102
Impact of adherence to statins on coronary artery disease in primary prevention
Bouchard, M.-H., Dragomir, A., Blais, L., Bérard, A., Pilon, D., & Perreault, S. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02828.x · Cited by 102
Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy
Benner, J. S., Chapman, R. H., Petrilla, A. A., Tang, S. S. K., Rosenberg, N., & Schwartz, J. S. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080238 · Cited by 102
The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
The FIELD Study Investigators (2004) · Cardiovascular Diabetology · doi:10.1186/1475-2840-3-9 · Cited by 101
Trends in the Prevalence, Awareness, Treatment, and Control of Cardiovascular Disease Risk Factors among Noninstitutionalized Patients with a History of Myocardial Infarction and Stroke
Muntner, P., DeSalvo, K. B., Wildman, R. P., Raggi, P., He, J., & Whelton, P. K. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj124 · Cited by 101
Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The Pravastatin in Acute Coronary Treatment (PACT) trial
Thompson, P. L., Meredith, I. T., Amerena, J. V., Campbell, T. J., Sloman, J. G., & Harris, P. J. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.10.052 · Cited by 101
Analysis of five HMG‐CoA reductase inhibitors— atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies
Pasha, M. K., Syed, M., Shaik, J. S., Shashikumar, D., Mullangi, R., & Srinivas, N. R. (2005) · Biomedical Chromatography · doi:10.1002/bmc.561 · Cited by 100
Pharmacology of 3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin
Igel, M., Sudhop, T., & von Bergmann, K. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002401102731 · Cited by 100
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel
Shepherd, J., Betteridge, J. D., Gaal, L. V., & Panel, O. B. O. A. E. C. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43677 · Cited by 100
A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice
Ando, Y., Shimizugawa, T., Takeshita, S., Ono, M., Shimamura, M., Koishi, R., & Furukawa, H. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300031-jlr200 · Cited by 100
Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes
Grant, R. W., Cagliero, E., Murphy-Sheehy, P., Singer, D. E., Nathan, D. M., & Meigs, J. B. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01103-8 · Cited by 100
Spironolactone use and renal toxicity: population based longitudinal analysis
Li, W., Struthers, A. D., Fahey, T. P., Watson, A. D., & MacDonald, T. M. (2010) · BMJ · doi:10.1136/bmj.c1768 · Cited by 99
Statins: Then and Now
Toth, P. P., & Banach, M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-23 · Cited by 99
Red Yeast Rice for Hypercholesterolemia
Cicero, A. F. G., Fogacci, F., & Banach, M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-3-192 · Cited by 99
Cardiovascular Antioxidant Therapy
Tinkel, J. L., Hassanain, H. H., & Khouri, S. J. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e31823dbbad · Cited by 99
Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction in Japanese
Sakamoto, T., Kojima, S., Ogawa, H., Shimomura, H., Kimura, K., Ogata, Y., Sakaino, N., & Kitagawa, A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.031 · Cited by 99
Atherogenesis: the role of inflammation and infection
Mahmoudi, M., Curzen, N. P., & Gallagher, P. J. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02503.x · Cited by 99
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: An 8-year retrospective cohort study
Clark, L. L., Ikonomidis, J. S., Crawford, F. A., Crumbley, A. J., Kratz, J. M., Stroud, M. R., Woolson, R. F., Bruce, J. J., Nicholas, J. S., Lackland, D. T., et al. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2005.11.006 · Cited by 99
Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials
Rahimi, K., Bhala, N. B., Kamphuisen, P. W., Emberson, J., Biere‐Rafi, S., Krane, V., Robertson, M., Wikstrand, J., & McMurray, J. J. V. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001310 · Cited by 99
Therapy With Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors (Statins) and Associated Risk of Incident Cardiovascular Events in Older Adults
Lemaître, R. N., Psaty, B. M., Heckbert, S. R., Kronmal, R. A., Newman, A. B., & Burke, G. L. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.12.1395 · Cited by 99
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants
Barylski, M., Nikfar, S., Mikhailidis, D. P., Toth, P. P., Salari, P., Ray, K. K., Pencina, M. J., Rizzo, M., Rysz, J., Abdollahi, M., et al. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.007 · Cited by 98
Cholesterol-Lowering Interventions and Stroke
Caterina, R. D., Scarano, M., Marfisi, R., Lucisano, G., Palma, F., Tatasciore, A., & Marchioli, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.062 · Cited by 98
High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes
Denegri, A., & Boriani, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200717090334 · Cited by 98
Hepatotoxicity Fears Contribute to Underutilization of Statin Medications by Primary Care Physicians
Rzouq, F. S., Volk, M. L., Hatoum, H. H., Talluri, S., Mummadi, R. R., & Sood, G. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181e15da8 · Cited by 98
Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-β, and fibronectin with concomitant increase in nitric oxide bioavailability
Zhou, M.-S., Schulman, I. H., Jaimes, E. A., & Raij, L. R. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00041.2008 · Cited by 98
Safety considerations for statins
Bolego, C., Baetta, R., Bellosta, S., Corsini, A., & Paoletti, R. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00007 · Cited by 98
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97
Targeting LOX‐1 in atherosclerosis and vasculopathy: current knowledge and future perspectives
Tian, K., Ogura, S., Little, P. J., Xu, S., & Sawamura, T. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13984 · Cited by 97
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
Goldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 99
Anti-inflammatory Nanomedicine for Cardiovascular Disease
Katsuki, S., Matoba, T., Koga, J., Nakano, K., & Egashira, K. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00087 · Cited by 97
Aggressive Lipid Lowering Does Not Improve Endothelial Function in Type 2 Diabetes
van Venrooij, F. V., van de Ree, M. A., Bots, M. L., Stolk, R. P., Huisman, M. V., Banga, J. D., & on behalf of the DALI Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1211 · Cited by 97
A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects — the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action
Sumi, D., Hayashi, T., Thakur, N. K., Jayachandran, M., Asai, Y., Kano, H., Matsui, H., & Iguchi, A. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00597-9 · Cited by 97
An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines
Ansell, B. J. (1999) · JAMA · doi:10.1001/jama.282.21.2051 · Cited by 97
Statin use and the risk of breast cancer
Beck, P. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00614-5 · Cited by 97
Cholesterol Reduction and Stroke Occurrence: An Overview of Randomized Clinical Trials
Mascio, R. D., Marchioli, R., & Tognoni, G. (2000) · Cerebrovascular Diseases · doi:10.1159/000016035 · Cited by 97
The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease
Mihos, C. G., Salas, M. J., & Santana, O. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181f52a7f · Cited by 96
Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
Lee, M. M. Y., Sattar, N. A., McMurray, J. J. V., & Packard, C. J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0800-z · Cited by 96
Primary Prevention of Coronary Heart Disease
Ballantyne, C. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6642-1 · Cited by 96
Understanding Postprandial Inflammation and Its Relationship to Lifestyle Behaviour and Metabolic Diseases
Klop, B., Proctor, S. D., Mamo, J. C. L., Botham, K. M., & Cabezas, M. C. (2011) · International Journal of Vascular Medicine · doi:10.1155/2012/947417 · Cited by 96
PROTECT
Ovbiagele, B. I., Saver, J. L., Fredieu, A., Suzuki, S., McNair, N. D., Dandekar, A., Razinia, T., & Kidwell, C. S. (2004) · Neurology · doi:10.1212/01.wnl.0000140493.83607.f1 · Cited by 96
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia
Ayyobi, A. F., & Brunzell, J. D. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00613-1 · Cited by 96
Coronary plaque as a replacement for age as a risk factor in global risk assessment
Grundy, S. M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01712-x · Cited by 96
Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation
KEOGH, A. M., Macdonald, P. S., Kaan, A., Aboyoun, C. L., Spratt, P. M., & Mundy, J. A. (2000) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(00)00077-2 · Cited by 96
Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Ginsberg, H. N., Bonds, D. E., Lovato, L. C., Crouse, J. R., Elam, M. B., Linz, P. E., O’Connor, P. J., Leiter, L. A., Weiss, D., Lipkin, E., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.024 · Cited by 95
Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk
Lin, I., Sung, J., Sanchez, R. J., Mallya, U. G., Friedman, M., Panaccio, M. P., Koren, A., Neumann, P. J., & Menzin, J. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.6.685 · Cited by 95
Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells
Scharnagl, H., Schinker, R., Gierens, H., Nauck, M., Wieland, H., & März, W. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00790-0 · Cited by 95
Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels
Tsevat, J., Kuntz, K. M., Orav, E. J., Weinstein, M. C., Sacks, F. M., & Goldman, L. (2001) · American Heart Journal · doi:10.1067/mhj.2001.114805 · Cited by 95
Hyperlipidemia Promotes Thrombosis After Injury to Atherosclerotic Vessels in Apolipoprotein E–Deficient Mice
Eitzman, D. T., Westrick, R. J., Xu, Z., Tyson, J., & Ginsburg, D. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.7.1831 · Cited by 95
THE MRC/BHF HEART PROTECTION STUDY: PRELIMINARY RESULTS
Owen, O. G. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11192.x · Cited by 95
Hormone replacement therapy: current controversies
Davison, S. L., & Davis, S. R. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01774.x · Cited by 94
Diabetes, hyperlipidemia, and coronary artery disease
Haffner, S. M. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00213-1 · Cited by 94
Managing dyslipidemia in chronic kidney disease
Weiner, D. E., & Sarnak, M. J. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.40049.x · Cited by 94
LDL Cholesterol: The Lower the Better
Martin, S. S., Blumenthal, R. S., & Miller, M. J. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.01.009 · Cited by 94
Stabilization of Carotid Atheroma Assessed by Quantitative Ultrasound Analysis in Nonhypercholesterolemic Patients With Coronary Artery Disease
Watanabe, K., Sugiyama, S., Kugiyama, K., Honda, O., Fukushima, H., Koga, H., Horibata, Y., Hirai, T., Sakamoto, T., Yoshimura, M., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.070 · Cited by 94
Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects
Omori, H., Nagashima, H., Tsurumi, Y., Takagi, A., Ishizuka, N., Hagiwara, N., Kawana, M., & Kasanuki, H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01677.x · Cited by 94
Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus
Ginsberg, H. N., & Illingworth, D. R. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01831-8 · Cited by 94
Atherogenesis: current understanding of the causes of atheroma
Weissberg, P. L. (2000) · Heart · doi:10.1136/heart.83.2.247 · Cited by 94
Prevention of heart failure
Baker, D. W. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.0805333 · Cited by 94
CHOLESTEROL AS AN INDEPENDENT PREDICTOR OF OUTCOME AFTER RENAL TRANSPLANTATION
Roodnat, J. I., Mulder, P. G. H., Zietse, R., Rischen-Vos, J., van Riemsdijk, I. C., IJzermans, J. N. M., & Weimar, W. W. (2000) · Transplantation · doi:10.1097/00007890-200004270-00029 · Cited by 94
Statins alter neutrophil migration by modulating cellular Rho activity–a potential mechanism for statins-mediated pleotropic effects?
Maher, B. M., Dhonnchu, T. N., Burke, J. P., Soo, A., Wood, A. E., & Watson, R. W. G. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0608382 · Cited by 93
Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803
Ng, K., Ogino, S., Meyerhardt, J. A., Chan, J. A., Chan, A. T., Niedzwiecki, D., Hollis, D. R., Saltz, L. B., Mayer, R. J., Benson, A. B., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr307 · Cited by 93
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome
Link, A., Ayadhi, T., Böhm, M., & Nickenig, G. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl277 · Cited by 93
Simvastatin Treatment Ameliorates Autoimmune Disease Associated with Accelerated Atherosclerosis in a Murine Lupus Model
Aprahamian, T. R., Bonegio, R. G. B., Rizzo, J. L., Perlman, H., Lefer, D. J., Rifkin, I. R., & Walsh, K. X. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3028 · Cited by 93
Are preventive drugs preventive enough? A study of patients’ expectation of benefit from preventive drugs
Trewby, P., Reddy, A., Trewby, C., Ashton, V., Brennan, G., & Inglis, J. (2002) · Clinical Medicine · doi:10.7861/clinmedicine.2-6-527 · Cited by 93
Cellular and molecular mechanisms of statins: an update on pleiotropic effects
Satoh, M., Takahashi, Y., Tabuchi, T., Minami, Y., Tamada, M., Takahashi, K., Itoh, T., Morino, Y., & Nakamura, M. (2015) · Clinical Science · doi:10.1042/cs20150027 · Cited by 92
Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment
Kini, A. S., Vengrenyuk, Y., Shameer, K., Maehara, A., Meerarani, P., Yoshimura, T., Matsumura, M., Aquino, M. B., Haider, N., Johnson, K. W., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.029 · Cited by 92
Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: A multicenter Italian study
Mannarino, E., Pirro, M., Cortese, C., Lupattelli, G., Siepi, D., Mezzetti, A., Bertolini, S., Parillo, M., Fellin, R., Pujia, A., et al. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.03.012 · Cited by 92
Compliance with a statin treatment in a usual-care setting:Retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia
Caspard, H., Chan, K. A., & Walker, A. M. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.005 · Cited by 92
Type 2 diabetes, dyslipidemia, and vascular risk: Rationale and evidence for correcting the lipid imbalance
Carmena, R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.04.027 · Cited by 92
ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin
Kajinami, K., Brousseau, M. E., Nartsupha, C., Ordovás, J. M., & Schaefer, E. J. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300278-jlr200 · Cited by 92
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management
Kajinami, K., Takekoshi, N., Brousseau, M. E., & Schaefer, E. J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.09.004 · Cited by 92
Optimal Windows of Statin Use for Immediate Infarct Limitation
Sanada, S., Asanuma, H., Minamino, T., Node, K., Takashima, S., Okuda, H., Shinozaki, Y., Ogai, A., Fujita, M., Hirata, A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143830.59419.73 · Cited by 92
Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years
Simons, L. A., Simons, J., Friedlander, Y., & McCallum, J. C. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00495-6 · Cited by 92
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes
Colhoun, H. M., Thomason, M. J., Mackness, M., Maton, S., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Fuller, J., & the CARDS Investigators (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00643.x · Cited by 92
The Effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10: Possible Biochemical/Clinical Implications
Hargreaves, I. P., Duncan, A. J., Heales, S. J. R., & Land, J. M. (2005) · Drug Safety · doi:10.2165/00002018-200528080-00002 · Cited by 91
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 91
The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) Study: Rationale and Methods
Murphy, T. P., Cooper, C. J., Dworkin, L. D., Henrich, W. L., Rundback, J. H., Matsumoto, A. H., Jamerson, K., & D’Agostino, R. B. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000176301.69756.28 · Cited by 91
Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy
Corrao, G., Conti, V., Merlino, L. G., Catapano, A. L., & Mancia, G. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.02.004 · Cited by 91
A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial
Illingworth, D. R., Crouse, J. R., Hunninghake, D. B., Davidson, M., Escobar, I. D., Stalenhoef, A. F. H., Paragh, G., Ma, P. T. S., Liu, M., Melino, M. R., et al. (2001) · Current Medical Research and Opinion · doi:10.1185/03007990152005351 · Cited by 91
Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins
Sirvent, P., Fabre, O., Bordenave, S., Hillaire-Buys, D., Raynaud De Mauverger, E., Lacampagne, A., & Mercier, J. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.01.008 · Cited by 90
The role of statins in the differentiation and function of bone cells
Chamani, S., Liberale, L., Mobasheri, L., Montecucco, F., Al‐Rasadi, K., Jamialahmadi, T., & Sahebkar, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13534 · Cited by 90
Effects of Atorvastatin on Coronary Flow Reserve in Patients with Slow Coronary Flow
Çalışkan, M., Erdoğan, D., Güllü, H., Topçu, S., Çiftçi, Ö., Yı́ldı́rı́r, A., & Müderrisoğlu, H. (2007) · Clinical Cardiology · doi:10.1002/clc.20140 · Cited by 90
Statins and Cancer Development
Duncan, R. E., El‐Sohemy, A., & Archer, M. C. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0027 · Cited by 90
The monocyte/macrophage as a therapeutic target in atherosclerosis
Saha, P., Modarai, B., Humphries, J., Mattock, K., Waltham, M., Burnand, K. G., & Smith, A. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.017 · Cited by 89
Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1–induced preeclampsia
Fox, K. A., Longo, M., Tamayo, E. H., Kechichian, T. B., Bytautiene, E., Hankins, G. D. V., Saade, G. R., & Costantine, M. M. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.083 · Cited by 89
Use of Propensity Score Technique to Account for Exposure-Related Covariates
Seeger, J. D., Kurth, T., & Walker, A. M. (2007) · Medical Care · doi:10.1097/mlr.0b013e318074ce79 · Cited by 89
Statin‐Associated Peripheral Neuropathy: Review of the Literature
Chong, P. H., Boskovich, A., Stevkovic, N., & Bartt, R. E. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1194.38084 · Cited by 89
Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey
Park, J. E., Chiang, C., Munawar, M., Pham, G. K., Sukonthasarn, A., Aquino, A. R., Lin, K. K., & Chan, H. W. R. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826710397100 · Cited by 89
Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials
Wei, L., Ebrahim, S. B. J., Bartlett, C., Davey, P., Sullivan, F., & MacDonald, T. M. (2005) · BMJ · doi:10.1136/bmj.38398.408032.8f · Cited by 89
Pravastatin down-regulates inflammatory mediators in human monocytes in vitro
Grip, O., Janciauskiene, S. M., & Lindgren, S. C. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00870-0 · Cited by 89
Diabetes and Cardiovascular Diseases
Kaur, J., Singh, P., & Sowers, J. R. (2002) · American Journal of Therapeutics · doi:10.1097/00045391-200211000-00009 · Cited by 89

Authors: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Affiliations: The University of Sydney (AU)
Corresponding author: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-11-05
Volume: 339
Issue: 19
Pages: 1349-1357
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199811053391902
OpenAlex: W38523360
Cited by: 5,261
References: 21
Citations by year: 2026: 19 · 2025: 24 · 2024: 57 · 2023: 53 · 2022: 60 · 2021: 58 · 2020: 72 · 2019: 82 · 2018: 81 · 2017: 94 · 2016: 114 · 2015: 111 · 2014: 118 · 2013: 167 · 2012: 147
FWCI: 312.19
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
UWA Profiles and Research Repository (UWA) (submittedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: pravastatin, coronary artery disease, statin therapy, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, coronary revascularization, total cholesterol, secondary prevention, lipid-lowering diet
MeSH terms: Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Mortality, Myocardial Infarction, Risk, Incidence, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks